Interleukin 2 production was studied in a family with systemic lupus erythematosus (SLE) and a C4QO heterozygous inheritance. Autoimmune manifestations seemed to be associated with the HLA haplotype containing the C4QO allele, which was shared by all four ill family members. Concentrations of interleukin 2, however, did not associate either with the haplotype or with the clinical or serological manifestations, as diminished concentrations of interleulin 2 were found in only two subjects with SLE. Thus the defect in this family seemed to be acquired rather than genetically conditioned.
Since the pioneering descriptions of a deficient production of interleukin 2 in autoimmune animal models' 2 a series of reports have described defects in the production of interleukin 2 in response interleukin 2 in subjects with SLE. With this aim major histocompatibility complex antigens and mitogen induced secretion of interleukin 2 were determined in several members of a family with SLE. The figure shows the pedigree and HLA haplotypes of this family. The table shows the concentrations of interleukin 2 induced by phytohaemagglutinin and the serological and clinical features of each family member. Undefined genetic factors, probably linked to the genome of the proband's mother, seemed to account for the disease process, as only the proband's mother and her first degree relatives had autoimmune manifestations. The genetic causative agent could be associated with the HLAhaplotype-A25, B18, Bw6, DRX, DQwl, DRw52, C4AQO, C4B1, C2C, BfS, GloSshared by all affected members and carrying the C4QO allele, which has been described as more prevalent among those with SLE,20 21 The above results indicate that interleukin 2 deficiency in SLE is not a genetically conditioned primary defect. If the defect were genetically determined and linked to an autoimmune trait, all affected members would be expected to synthesise low concentrations of interleukin 2. Two subjects with autoimmune disease secreted normal amounts of interleukin 2, however. Furthermore, the defect did not seem to be a consequence of autoantibody-cell antigen interactions or receptor occupancy by immune complexes as some patients secreted autoantibodies while producing interleukin 2 in normal concentrations.
Although more families should be studied before reaching a definite conclusion, our data indicate that interleukin 2 deficiency in SLE is an acquired rather than a genetic defect. Similar conclusions were obtained in a recent study of interleukin 2 production in monozygotic twins with SLE.22 systemic lupus erythematosus and a C4Q0
